Bayer sets $22.3B budget for R&D, new plants

Bayer plans to spend a combined €15 billion ($22.3 billion) on research and development, plants and equipment until 2013, its Chief Executive Marijn Dekkers (photo) said at the company's annual meeting. About two-thirds of that will go to R&D. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.